Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once‐daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology
Hauptverfasser: Reau, Nancy, Kwo, Paul Y., Rhee, Susan, Brown, Robert S., Agarwal, Kosh, Angus, Peter, Gane, Edward, Kao, Jia‐Horng, Mantry, Parvez S., Mutimer, David, Reddy, K. Rajender, Tran, Tram T., Hu, Yiran B., Gulati, Abhishek, Krishnan, Preethi, Dumas, Emily O., Porcalla, Ariel, Shulman, Nancy S., Liu, Wei, Samanta, Suvajit, Trinh, Roger, Forns, Xavier
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220874/
https://ncbi.nlm.nih.gov/pubmed/29672891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30046
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge